We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blocking Uncontrolled Calcium Flux Protects the Brain from Stroke Damage

By LabMedica International staff writers
Posted on 04 Feb 2010
Preventing the binding of a proapoptotic enzyme during stroke (cerebral ischemia) protected the brain from damage caused by the unregulated transport of calcium ions into nerve cells.

Investigators at the University of Central Florida (Orlando, USA) and their collaborators at Louisiana State University (New Orleans, USA) worked with a mouse stroke model. More...
They focused their efforts on understanding the role of an enzyme called death-associated protein kinase 1 (DAPK1), which was known to be a positive mediator of gamma-interferon induced programmed cell death.

The Investigators found that under the traumatic conditions induced by a stroke DAPK1 attached to and blocked the activity of NMDA (N-methyl-D-aspartate) receptors that normally control calcium flux in nerve cells. Lacking NMDA receptor control, nerve cells became overloaded with calcium and died.

To prevent damage from calcium overload the investigators resorted to two different types of therapy. In one study, they used gene-silencing techniques to eliminate DAPK1 from nerve cells. In another, they treated brain tissue with a soluble polypeptide, NR2BCT, which mimicked the region of the NMDA receptor that binds DAPK1. The peptide bound to DAPK1 more efficiently and prevented the enzyme from attaching to the NMDA receptor. In both cases, the treatment protected brain cells against stroke injury, and did not affect the normal physiological functions of the receptors.

Results published in the January 22, 2010, issue of the journal Cell confirmed that DAPK1 physically and functionally interacted with the NMDA receptor NR2B subunit at extrasynaptic sites, and this interaction acted as a central mediator for stroke damage.

"It is conceivable that this study not only provides new insights into the cellular and molecular basis responsible for stroke damage, but also provides a therapeutic target for stroke therapy," said senior author Dr. Youming Lu, professor of neurosciences at Louisiana State University.

Related Links:
University of Central Florida
Louisiana State University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.